News
Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...
Learn how the benefits of GLP-1s may be outweighed by the risks.
Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the future.
Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...
The drug coverage provision does not mention any specific drug by name, but it could include the GLP-1 agonists, such as ...
Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?
The recent approval of weight-loss drug Wegovy in New Zealand has been hyped as a breakthrough in the country’s fight against ...
Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...
The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug ...
8h
Money Talks News on MSNYour Wegovy Access Just Changed: What Patients Need to Know NowNovo Nordisk just pulled Wegovy from a major telehealth platform over safety concerns about knockoff versions. Here's what ...
The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results